Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 8;11:7781. doi: 10.1038/s41598-021-87435-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

GSB-106 promotes survival of serum-deprived SH-SY5Y cells through TrkB and downstream signaling pathways. (A) Survival analysis of serum-deprived SH-SY5Y cells (2 × 10⁵/well) incubated with BDNF (1 nmol), GSB-106 (100 nmol) in the presence of K252a (500 nmol) for 48 h. Cell viability was normalized to viability in BDNF group (n = 5; ^#p < 0.05 in relation to 0% FBS-control; *p < 0.05; in relation to agonist without inhibitor; Wilcoxon t-test). (B) Survival analysis of serum-deprived SH-SY5Y cells (2 × 10⁵/well) incubated with BDNF (1 nmol), GSB-106 (100 nmol) in the presence of PP2 (100 μmol) for 48 h. Cell viability was normalized to viability in BDNF group (n = 5; ^#p < 0.05 in relation to 0% FBS-control; *p < 0.05; in relation to agonist without inhibitor; Wilcoxon t-test). (C) Survival analysis of serum-deprived SH-SY5Y cells (2 × 10⁵/well) incubated with BDNF (1 nmol), GSB-106 (100 nmol) in the presence of PD98059 (50 μmol) for 48 h. Cell viability was normalized to viability in BDNF group (n = 5; ^#p < 0.05 in relation to 0% FBS-control; *p < 0.05; in relation to agonist without inhibitor; Wilcoxon t-test). (D) Survival analysis of serum-deprived SH-SY5Y cells (2 × 10⁵/well) incubated with BDNF (1 nmol), GSB-106 (100 nmol) in the presence of LY294002 (1 μmol) for 48 h. Cell viability was normalized to viability in BDNF group (n = 5; ^#p < 0.05 in relation to 0% FBS-control; *p < 0.05; in relation to agonist without inhibitor; Wilcoxon t-test).